Clay Siegall is the current CEO and the President of Seattle Genetics, a major institution focusing on research, drug development, and cancer treatment technology. As the CEO, Clay oversees the company’s short and long-term plans in addition to the role of a figurehead when it comes to meeting investors, partners, and reporters. Besides monitoring the operations of Seattle Genetics, Clay also runs an informative blog that offers advice on genetics, scientific discoveries and developments in cancer therapy. Clay earned a Bachelor of Science in Zoology from the University of Maryland and later a Ph.D. in Genetics from George Washington University.
Under the guidance of Clay Siegall, Seattle Genetics has become one of the best-performing institutions in cancer research. With the relatively recent launch of the ADC technology, Seattle Genetics has made numerous steps towards providing the world with a dependable means of fighting cancer. ADC technology works on the concept of eliminating cancer infected body cells without affecting the healthy cells. Before this technology, it was hard to direct rays to the cancer cells without meddling with healthy cells. Seattle Genetics, under the leadership of Clay, has worked hard to develop this technology that is now providing safe and reliable solutions to cancer patients.
Between 1988 and 1991, before co-founding Seattle Genetics, Clay served at the National Institutes of Health and the National Cancer Institute. He later joined Bristol-Myers Squibb Pharmaceutical Research Institute where he worked from 1991 to 1997. Besides managing Seattle Genetics, Clay serves on the Board of Governors of the Washington Biotechnology and Biomedical Association, Alder Bio-pharmaceuticals, and Fred Hutchinson Cancer Research Business Alliance.
In the fight against cancer, Seattle Genetics is focusing on address different types of autoimmunity and cancer symptoms by conducting experiments that help in drugs development. Currently, Seattle Genetics is developing several cancer drugs. One of the medicines that are in clinical analysis stage is 33A, and it will be used to treat myeloid leukemia. The firm has also reported that breast and bladder cancer drugs are in their last stages of development. Besides, it is also conducting an innovative clinical study for a Hodgkin’s lymphoma drug, ADCETRIS.